<DOC>
	<DOCNO>NCT02086903</DOCNO>
	<brief_summary>To evaluate pharmacodynamics low Ticagrelor dose healthy Korean volunteer compare standard Clopidogrel agent .</brief_summary>
	<brief_title>Clopidogrel And Ticagrelor Healthy Subjects</brief_title>
	<detailed_description>Consist previous study Ticagrelor great , faster platelet inhibition effect Clopidogrel healthy subject stable coronary artery disease patient . Moreover , Asian subject expose higher active metabolite strong pharmacodynamics response European subject oral dose antiplatelet agent . However , previous report compare efficacy safety Ticagrelor Clopidogrel healthy Asian ethnicity lack . Therefore , aim study evaluate pharmacodynamic response low Ticagrelor dose use laboratory platelet function test healthy Korean volunteer .</detailed_description>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>12 healthy men Aged 19 59 year Body mass index ( BMI ) 18.5 29.9 kg/m2 Baseline maximal platelet aggregation ( MPA ) 10 Î¼mol/L ADP 65 % To screen standard result usual clinical test A history bleeding within 6 month Bleeding diathesis Hemoglobin &lt; 12g/dl History antiplatelet anticoagulation treatment within 1 month contraindication study drug Severe hepatic dysfunction ( serum liver enzyme bilirubin &gt; 3 time normal limit ) Patients hereditary disease galactose intolerance , lactase deficiency , glucosegalactose malabsorption Previous experience clinical trial within three month</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Ticagrelor</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Platelet function test</keyword>
</DOC>